About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT04645199

National Longitudinal Cohort of Hematological Diseases

Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limite...

Lead sponsor: Institute of Hematology & Blood Diseases Hospital, China•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Zhen Song, MD

CONTACT

+86 02223909051 cir@ihcams.ac.cn

Sponsors

Lead Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020.

Exclusion Criteria

•Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
•Alcohol and drug addictions affect their ability to comply with study requirements.
•According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.

Related studies

RECRUITINGPhase 1/2

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960 · Multiple Myeloma

RECRUITINGPhase 1

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

NCT06197672 · Acute Myeloid Leukemia

RECRUITINGPhase 1

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890 · Acute Myeloid Leukemia

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

RECRUITINGPhase 2

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

NCT07425782 · Acute Myeloid Leukemia, Consolidation Therapy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 12, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment2,300

Start dateDec 2020

Last updatedFeb 12, 2026

Condition

Multiple Myeloma Acute Myeloid Leukemia Hemophilia Hemophilia A Hemophilia B+12 more

Locations shown

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions